Avidity biosciences announces arthur a. levin to join board of directors and transition to distinguished scientist and strategic leader

W. michael flanagan, ph.d. named chief scientific and technical officer san diego , feb. 23, 2023 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that arthur a.
RNA Ratings Summary
RNA Quant Ranking